(Reuters) – A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV in a patent dispute over Biogen Inc’s blockbuster multiple sclerosis drug Tecfidera, sending the drugmaker’s shares down 7%.
The ruling comes months after the U.S. Court of Appeals for the Federal Circuit ruled that a bioequivalent version of Tecfidera made by Banner Life Sciences LLC does not infringe a Biogen patent that was set to expire in June.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur)
